ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, also known as Gleevec or Glivec (Novartis, Basel, Switzerland; formerly referred to as STI571 or CGP57148B), inhibits protein TKs of the ABL-family and is used for therapy of chronic myeloid leukemia in humans (57).